{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T05:06:44Z","timestamp":1782277604416,"version":"3.54.5"},"reference-count":36,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100003621","name":"Ministry of Science, ICT and Future Planning","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003621","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["NRF-2018R1A4A1022513"],"award-info":[{"award-number":["NRF-2018R1A4A1022513"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004085","name":"Ministry of Education, Science and Technology","doi-asserted-by":"publisher","award":["2017 R1D1A1B03029582"],"award-info":[{"award-number":["2017 R1D1A1B03029582"]}],"id":[{"id":"10.13039\/501100004085","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thrombosisresearch.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Thrombosis Research"],"published-print":{"date-parts":[[2020,9]]},"DOI":"10.1016\/j.thromres.2020.06.045","type":"journal-article","created":{"date-parts":[[2020,6,27]],"date-time":"2020-06-27T00:33:10Z","timestamp":1593217990000},"page":"154-159","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["MED-TMA: A clinical decision support tool for differential diagnosis of TMA with enhanced accuracy using an ensemble method"],"prefix":"10.1016","volume":"193","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1456-2392","authenticated-orcid":false,"given":"Jeesun","family":"Yoon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3458-1440","authenticated-orcid":false,"given":"Sungyoung","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Choong-Hyun","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daeyoon","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inho","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sung-Soo","family":"Yoon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Doyeun","family":"Oh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongseok","family":"Yun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youngil","family":"Koh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"19","key":"10.1016\/j.thromres.2020.06.045_bb0005","first-page":"1847","article-title":"Syndromes of thrombotic microangiopathy","volume":"371","author":"George","year":"2014","journal-title":"N Engl J Med"},{"issue":"4\u20135","key":"10.1016\/j.thromres.2020.06.045_bb0010","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1016\/j.autrev.2014.01.004","article-title":"Thrombotic thrombocytopenic purpura and other thrombotic microangiopathic hemolytic anemias: diagnosis and classification","volume":"13","author":"Shenkman","year":"2014","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.thromres.2020.06.045_bb0015","doi-asserted-by":"crossref","first-page":"17020","DOI":"10.1038\/nrdp.2017.20","article-title":"Thrombotic thrombocytopenic purpura","volume":"3","author":"Kremer Hovinga","year":"2017","journal-title":"Nat Rev Dis Primers"},{"issue":"10095","key":"10.1016\/j.thromres.2020.06.045_bb0020","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/S0140-6736(17)30062-4","article-title":"Haemolytic uraemic syndrome","volume":"390","author":"Fakhouri","year":"2017","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.thromres.2020.06.045_bb0025","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1111\/bjh.13658","article-title":"Impact of severe ADAMTS13 deficiency on clinical presentation and outcomes in patients with thrombotic microangiopathies: the experience of the Harvard TMA Research Collaborative","volume":"171","author":"Bendapudi","year":"2015","journal-title":"Br J Haematol"},{"issue":"10","key":"10.1016\/j.thromres.2020.06.045_bb0030","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1111\/jth.13764","article-title":"Thrombotic thrombocytopenic purpura: pathogenesis, diagnosis and potential novel therapeutics","volume":"15","author":"Saha","year":"2017","journal-title":"J Thromb Haemost"},{"issue":"11","key":"10.1016\/j.thromres.2020.06.045_bb0035","doi-asserted-by":"crossref","first-page":"4043","DOI":"10.1182\/blood-2003-11-4035","article-title":"Effect of plasma exchange on plasma ADAMTS13 metalloprotease activity, inhibitor level, and clinical outcome in patients with idiopathic and nonidiopathic thrombotic thrombocytopenic purpura","volume":"103","author":"Zheng","year":"2004","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.thromres.2020.06.045_bb0040","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1002\/ajh.24559","article-title":"Efficacy of a rituximab regimen based on B cell depletion in thrombotic thrombocytopenic purpura with suboptimal response to standard treatment: results of a phase II, multicenter noncomparative study","volume":"91","author":"Benhamou","year":"2016","journal-title":"Am J Hematol"},{"issue":"20","key":"10.1016\/j.thromres.2020.06.045_bb0045","doi-asserted-by":"crossref","first-page":"4060","DOI":"10.1182\/blood-2010-07-271445","article-title":"How I treat patients with thrombotic thrombocytopenic purpura: 2010","volume":"116","author":"George","year":"2010","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.thromres.2020.06.045_bb0050","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1007\/s12185-016-2019-x","article-title":"Efficacy and safety of rituximab in Japanese patients with acquired thrombotic thrombocytopenic purpura refractory to conventional therapy","volume":"104","author":"Miyakawa","year":"2016","journal-title":"Int J Hematol"},{"issue":"5","key":"10.1016\/j.thromres.2020.06.045_bb0055","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1111\/bjh.13993","article-title":"Bortezomib in the treatment of refractory thrombotic thrombocytopenic purpura","volume":"173","author":"Patriquin","year":"2016","journal-title":"Br J Haematol"},{"issue":"25","key":"10.1016\/j.thromres.2020.06.045_bb0060","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1056\/NEJMc1603180","article-title":"Caplacizumab for acquired thrombotic thrombocytopenic purpura","volume":"374","author":"Peyvandi","year":"2016","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.thromres.2020.06.045_bb0065","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1056\/NEJMoa1806311","article-title":"Caplacizumab treatment for acquired thrombotic thrombocytopenic purpura","volume":"380","author":"Scully","year":"2019","journal-title":"N Engl J Med"},{"issue":"17","key":"10.1016\/j.thromres.2020.06.045_bb0070","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1056\/NEJMra0902814","article-title":"Atypical hemolytic-uremic syndrome","volume":"361","author":"Noris","year":"2009","journal-title":"N Engl J Med"},{"issue":"23","key":"10.1016\/j.thromres.2020.06.045_bb0075","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1056\/NEJMoa1208981","article-title":"Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome","volume":"368","author":"Legendre","year":"2013","journal-title":"N Engl J Med"},{"issue":"23","key":"10.1016\/j.thromres.2020.06.045_bb0080","doi-asserted-by":"crossref","first-page":"4777","DOI":"10.1182\/blood.V126.23.4777.4777","article-title":"First in human single-ascending dose study: safety, biomarker, pharmacokinetics and exposure-response relationships of ALXN1210, a humanized monoclonal antibody to C5, with marked half-life extension and potential for significantly longer dosing intervals","volume":"126","author":"Sahelijo","year":"2015","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.thromres.2020.06.045_bb0085","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1182\/blood-2018-09-876136","article-title":"Ravulizumab (ALXN1210) vs eculizumab in adult patients with PNH naive to complement inhibitors: the 301 study","volume":"133","author":"Lee","year":"2019","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.thromres.2020.06.045_bb0090","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1182\/blood-2002-02-0344","article-title":"Von Willebrand factor-cleaving protease (ADAMTS13) in thrombocytopenic disorders: a severely deficient activity is specific for thrombotic thrombocytopenic purpura","volume":"100","author":"Bianchi","year":"2002","journal-title":"Blood"},{"issue":"24","key":"10.1016\/j.thromres.2020.06.045_bb0095","doi-asserted-by":"crossref","first-page":"3733","DOI":"10.1182\/blood-2013-12-547067","article-title":"Biomarkers of terminal complement activation confirm the diagnosis of aHUS and differentiate aHUS from TTP","volume":"123","author":"Cataland","year":"2014","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.thromres.2020.06.045_bb0100","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1111\/trf.13359","article-title":"Effect of ADAMTS13 activity turnaround time on plasma utilization for suspected thrombotic thrombocytopenic purpura","volume":"56","author":"Connell","year":"2016","journal-title":"Transfusion"},{"issue":"6","key":"10.1016\/j.thromres.2020.06.045_bb0105","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1055\/s-2005-925472","article-title":"Molecular biology of ADAMTS13 and diagnostic utility of ADAMTS13 proteolytic activity and inhibitor assays","volume":"31","author":"Shelat","year":"2005","journal-title":"Semin Thromb Hemost"},{"issue":"4","key":"10.1016\/j.thromres.2020.06.045_bb0110","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1160\/TH03-11-0675","article-title":"An enzyme immunoassay of ADAMTS13 distinguishes patients with thrombotic thrombocytopenic purpura from normal individuals and carriers of ADAMTS13 mutations","volume":"91","author":"Zhou","year":"2004","journal-title":"Thromb Haemost"},{"issue":"1","key":"10.1016\/j.thromres.2020.06.045_bb0115","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1111\/j.1365-2141.2005.05420.x","article-title":"FRETS-VWF73, a first fluorogenic substrate for ADAMTS13 assay","volume":"129","author":"Kokame","year":"2005","journal-title":"Br J Haematol"},{"issue":"8","key":"10.1016\/j.thromres.2020.06.045_bb0120","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1111\/j.1537-2995.2010.02653.x","article-title":"The utility of patient characteristics in predicting severe ADAMTS13 deficiency and response to plasma exchange","volume":"50","author":"Bentley","year":"2010","journal-title":"Transfusion"},{"issue":"4","key":"10.1016\/j.thromres.2020.06.045_bb0125","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0010208","article-title":"Predictive features of severe acquired ADAMTS13 deficiency in idiopathic thrombotic microangiopathies: the French TMA reference center experience","volume":"5","author":"Coppo","year":"2010","journal-title":"PLoS One"},{"issue":"8","key":"10.1016\/j.thromres.2020.06.045_bb0130","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.3324\/haematol.2011.049676","article-title":"Development and validation of a predictive model for death in acquired severe ADAMTS13 deficiency-associated idiopathic thrombotic thrombocytopenic purpura: the French TMA Reference Center experience","volume":"97","author":"Benhamou","year":"2012","journal-title":"Haematologica"},{"issue":"4","key":"10.1016\/j.thromres.2020.06.045_bb0135","doi-asserted-by":"crossref","first-page":"e157","DOI":"10.1016\/S2352-3026(17)30026-1","article-title":"Derivation and external validation of the PLASMIC score for rapid assessment of adults with thrombotic microangiopathies: a cohort study","volume":"4","author":"Bendapudi","year":"2017","journal-title":"Lancet Haematol"},{"issue":"5","key":"10.1016\/j.thromres.2020.06.045_bb0140","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1097\/00004714-200110000-00006","article-title":"Clinical predictors of drug response in obsessive-compulsive disorder","volume":"21","author":"Erzegovesi","year":"2001","journal-title":"J Clin Psychopharmacol"},{"issue":"6871","key":"10.1016\/j.thromres.2020.06.045_bb0145","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1038\/415530a","article-title":"Gene expression profiling predicts clinical outcome of breast cancer","volume":"415","author":"van\u2019t Veer","year":"2002","journal-title":"Nature"},{"key":"10.1016\/j.thromres.2020.06.045_bb0150","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.thromres.2018.10.010","article-title":"Validation of the PLASMIC score, a clinical prediction tool for thrombotic thrombocytopenic purpura diagnosis, in Chinese patients","volume":"172","author":"Tang","year":"2018","journal-title":"Thromb Res"},{"issue":"Suppl. 1","key":"10.1016\/j.thromres.2020.06.045_bb0155","doi-asserted-by":"crossref","first-page":"2440","DOI":"10.1182\/blood-2018-99-111416","article-title":"Plasmic score in thrombotic microangiopathy may not be discriminatory in many instances","volume":"132","author":"Reddy","year":"2018","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.thromres.2020.06.045_bb0160","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/s12185-011-0771-5","article-title":"Clinical features of severe acquired ADAMTS13 deficiency in thrombotic thrombocytopenic purpura: the Korean TTP registry experience","volume":"93","author":"Jang","year":"2011","journal-title":"Int J Hematol"},{"issue":"4","key":"10.1016\/j.thromres.2020.06.045_bb0165","doi-asserted-by":"crossref","first-page":"2465","DOI":"10.1016\/j.eswa.2007.04.015","article-title":"AptaCDSS-E: a classifier ensemble-based clinical decision support system for cardiovascular disease level prediction","volume":"34","author":"Eom","year":"2008","journal-title":"Expert Syst Appl"},{"issue":"4","key":"10.1016\/j.thromres.2020.06.045_bb0170","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/j.transci.2017.06.006","article-title":"Validation of the PLASMIC score at a university medical center","volume":"56","author":"Jajosky","year":"2017","journal-title":"Transfus Apher Sci"},{"issue":"2","key":"10.1016\/j.thromres.2020.06.045_bb0175","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1093\/ajcp\/aqv086","article-title":"Pathology consultation on the diagnosis and treatment of thrombotic microangiopathies (TMAs)","volume":"145","author":"Williams","year":"2016","journal-title":"Am J Clin Pathol"},{"issue":"4","key":"10.1016\/j.thromres.2020.06.045_bb0180","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1002\/hon.2346","article-title":"Transplant-associated thrombotic microangiopathy: an unresolved complication of unrelated allogeneic transplant for hematologic diseases","volume":"35","author":"Sakellari","year":"2017","journal-title":"Hematol Oncol"}],"container-title":["Thrombosis Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049384820302875?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049384820302875?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T17:43:00Z","timestamp":1758735780000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049384820302875"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9]]},"references-count":36,"alternative-id":["S0049384820302875"],"URL":"https:\/\/doi.org\/10.1016\/j.thromres.2020.06.045","relation":{},"ISSN":["0049-3848"],"issn-type":[{"value":"0049-3848","type":"print"}],"subject":[],"published":{"date-parts":[[2020,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"MED-TMA: A clinical decision support tool for differential diagnosis of TMA with enhanced accuracy using an ensemble method","name":"articletitle","label":"Article Title"},{"value":"Thrombosis Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.thromres.2020.06.045","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}